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Abnormal left ventricular diastolic performance, an early
manifestation of hypertension in the heart, may precede
the development ofleft ventricular hypertrophy. To as-
sess effects of antihypertensive therapy on the heart, left
ventricular mass (determined by echocardiography) and
rapid left ventricular filling rate (determined by radio-
nuclide ventriculography) were compared before and
after 6 months of treatment of 16 patients. Nitrendipine
(a dihydropyridine calcium channel blocker) was given
alone or in combination with either propranolol or hy-
drochlorothiazide, or both, and significantly reduced blood
pressure (156/103 ± 12/7 to 137/89 ± 10/6 mm Hg),
In 6 of the 16 patients, left ventricular mass decreased
by more than 10% (270 ± 95 to 193 ± 47 g, P < 0.01);
Abnormalities of both systolic (1-3) and diastolic (4,5) per-
formance that appear during chronic left ventricular pressure
overload are generally proportional to the degree of left
ventricular hypertrophy. However, impaired left ventricular
filling can occur in the absence of echocardiographically
defined hypertrophy and may represent an early marker for
the pathologic effects of hypertension on the myocardium
(6-8). The present study was undertaken to determine whether
antihypertensive therapy reduces ventricular mass, and
whether these changes correlate with improved left ventric-
ular filling in hypertensive patients.
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in the same patients, left ventricular fillingrate increased
(2.03 ± 0.35to 2.30 ± 0.45end-diastoliccounts/s[EDC/s],
p < 0.01). In the one patient whose left ventricular mass
increased (137 to 195 g), left ventricular filling rate de-
creased from 2.01 to 1.78 EDC/s. In the remaining nine
patients who had no change in left ventricular mass,
there was no significant change in left ventricular filling.
The changes in ventricular mass and filling could not
be related to the extent of change in blood pressure or
heart rate. These data suggest that regression of left
ventricular mass during antihypertensive therapy with
nitrendipine is accompanied by improved diastolic
function.
(J Am Coil CardioI1986;8:1449-54)
Methods
Study patients. Twenty-two patients with mild to mod-
erate essential hypertension (supine diastolic blood pressure
between 90 and 115 mm Hg in the untreated state) were
recruited from the Hypertension and Cardiology Clinics of
the John Dempsey Hospital. Sixteen patients (mean age
46 ± 11 years; 14 men and 2 women) who had echocar-
diograms of acceptable quality for serial ventricular mass
calculations formed the study group. None of these patients
had a history of angina pectoris, myocardial infarction or
valvular heart disease, and none had evidence of coronary
artery disease by electrocardiography, radionuclide exercise
ventriculography or thallium scintigraphy. None of these
patients met electrocardiographic criteria for left ventricular
hypertrophy. Other patient characteristics are listed in Table
1. The study was approved by the University of Connecticut
Institutional Review Board and all subjects gave informed
consent.
Antihypertensive therapy protocol (Fig. 1). Antihy-
pertensive medications were withdrawn for 2 weeks, after
which the patients received placebo for 4 weeks. Baseline
measurements were taken during the fourth week of placebo
therapy. The study protocol required reduction of supine
0735-1097/86/$3.50
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Table 1. Patient Characteristics and Principal Findings
*AII probability values compare treatment with placebo. EDC = end-
diastolic counts; LV = left ventricular.
Figure 1. Study design (16 patients), The treatment objective
was to reducediastolic blood pressure by 10mm Hg if the baseline
diastolic blood pressure was 90 to 100 mm Hg, or to less than 90
mm Hg if the baseline diastolic blood pressure was greater than
100 mm Hg,
an M-mode echocardiogram was obtained, Calculations of
left ventricular mass were made from left ventricular di-
mensions obtained using the Penn measurement conventions
according to the method of Devereux and Reichek (9). The
relevant dimensions of three cardiac cycles were averaged
to form the basis of the mass calculation. Baseline and
treatment records were obtained during held expiration in
the same body and transducer positions, Patients took their
study medications on the day of the treatment echocardio-
gram, All echocardiograms were coded and read blindly in
random sequence by a single observer (V.S,),
To determine intraobserver variation, 10 sample echo-
cardiograms were again read by the observer after an interval
of 3 months. For the purposes of this study, variability was
determined in the following manner: The difference in left
ventricular mass between the first and second reading of a
given echocardiogram, divided by the mass obtained in the
first reading was the percent variation of the second reading,
The percent variation of the 10 sample echocardiograms
was then averaged; 2 standard deviations (2Z) were added
to the mean (X) of this calculation and multiplied by 100%.
The result was considered the percent variability (X +
2Z x 100%) for reading any two echocardiograms based
on the assumption that they were otherwise identical.
A "responder" was defined as a patient whose left ven-
tricular mass on the baseline echocardiogram exceeded the
value from the treatment echocardiogram by more than the
percent variability associated with the control echocardio-
grams. "Nonresponders" failed to show this extent of mass
reduction.
Left ventricular filling. Rapid left ventricular filling was
studied at the end of the placebo period and within 3 days
of the "treatment" echocardiograrn. To avoid immediate
hemodynamic effects of the drugs, patients were withdrawn
from treatment for 24 to 48 hours before the radionuclide
studies. After the patient's red blood cells were labeled with
technetium-99m, average rapid left ventricular filling rates
were calculated from nuclear probe-derived high resolution
time-activity curves with gamma camera validation of the
left ventricular region of interest as described elsewhere (4),
The results of three separate determinations of the region
of interest and the background constituted a session and
were averaged for the baseline and treatment values, re-
spectively. For the purposes of this study, the percent var-
iability that could be attributed to any session was calculated
as follows: The mean and standard deviation for the three
determinations of filling rate in a session were calculated.
The value of 2 standard deviations (2Z) was divided by the
mean value for filling rate for the session (X) and multiplied
by 100%, yielding a percent of the mean filling rate (%LVFR):
%LVFR = 2Z/X x 100%, The percent of the mean filling
rate was averaged for 10 control sessions.
A "responder" was defined as a patient in whom the
difference between the placebo and treatment rapid left ven-
Treatment
89 ± 6, P < 0.01
68 ± 8, p < 0.02*
137 ± )0, P < 0.01
222 ± 64, P = NS
2.\1 ± .54, p < 0.05
59 ± 4, P = NS
Placebo
103 ± 7
64 ± 7
156 ± 12
246 ± 94
1.95 ± .34
60 ± 4
Heart rate (beats/min)
Systolic blood pressure
(rnm Hg)
Diastolic blood pressure
(mm Hg)
LV mass (g)
LV filling rate (EDCls)
LV ejection fraction (%)
I Nitrendipine 2180 mglday (8 pts.)
/
Nilrendipine 20·80 mglday
Propranolol 20.8: mglday (6 pts.)
Entry ~--~.. PlaceboWashoul I
(8 Weeks) t
Nilrendipine 20·80 mglday
+
Propranolol 40·80 mg/day
+
diastolic blood pressure to less than 90 mm Hg if the baseline
blood pressure was greater than 100 mm Hg, or a reduction
of 10 mm Hg if the baseline diastolic blood pressure was
between 90 and 100 mm Hg. All patients were started on
treatment with nitrendipine at a dose of 5 mg twice daily
with weekly titration to a maximal daily dose of up to 80
mg to achieve the blood pressure goal. If nitrendipine
monotherapy failed to achieve the goal blood pressure, a
second drug was added: propranolol (up to 160 mg/day) or
hydrochlorothiazide (up to 50 mg/day), or both, The max-
imal time of nitrendipine monotherapy before the addition
of a second drug was 3 weeks, For patients taking hydro-
chlorothiazide, oral potassium chloride supplements were
administered when the serum potassium level fell below 3,5
mliq/liter.
Blood pressure and heart rate determinations. Heart
rate (electrocardiogram) and blood pressure (mercury col-
umn sphygomomanometer) were measured when the pa-
tients were supine for at least 5 minutes, The values reported
as the treatment response represent the average data from
two visits 2 to 4 weeks apart after 6 months of drug therapy,
Left ventricular mass. At the end of the placebo period,
and again after 6 months of antihypertensive drug therapy,
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Figure 2. Left ventricular ejectio n fraction (LVEF), heart rate
and systolic (SBP) and diastotic (DBP) blood pressure during pla-
cebo and active therapy. Responders are classified by left ven-
tricular mass change and are compared with nonresponders .
as a single group (64 =: 7 versus 68 .i: 8, P < 0.02), but
no differences in heart rate after drug therap y were seen in
the responders and the nonresponders (with respect to ven-
tricular mass and filling) (2 ± 5 versus 4 ± 6 beats/min ,
p = NS) (Fig. 2). Further, the difference s in heart rate
abated after 112 hour at rest , and thus were not a factor during
radionuclide studies (Table I).
Left ventricular wall thickness, chamber dimensions
and mass. Patterns of change were variable; the study group
was not large enough to ju stify grouping patients as re-
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tricular filling rate exceeded the mean percent of the mean
filling rate for the control sessions and was not associated
with a significant change in heart rate or ejection fraction .
The method to determine variability of left ventricular filling
rate differed from that used to assess intraobserver varia-
bility for echocardiograms because in the former , the var-
iability results from selection of the region of interest and
background , whereas in the latter, variability results from
observer choice of recorded echoes.
Ejection f raction was calculated by dividing the stroke
counts by end-diastolic counts with subtraction of the back-
ground activity. In our laboratory intraobserver variability
has been established at less than 3 absolute percent.
Statistical methods. The effect of antihypertensive ther-
apy on left ventricular mass and filling rate for the entire
group of 16 patients was evalu ated by means of a paired t
test. A two-tailed t test was used to characterize any dif-
ferences in the blood pressure , heart rate and ejection frac-
tion responses to treatment of responders and nonrespond-
ers. Statistical evaluations of the effects of individual treatment
regimens on responders and nonresponders with respect to
left ventricular mass and left ventricular filling were not
done in view of the small number of subjec ts in each group.
Variability of left ventricular mass and filling studies.
The mean (X) of the difference in ventricular mass between
the first and seco nd readings of the same echocardiogram
expressed as a percent of the baseline value was, for 10
echocardiograms, 0.04 ± 0.03%. Thus the variability due
to the observer was considered to be a maximum of 10%.
For the radionuclide studies of rapid ventricular filling, the
value of 2 standard deviations of a sess ion divided by the
mean was 0.042 when 10 sess ions were averaged. Thu s,
the maximal within-session variability resultin g from selec-
tion of region of interest and background was considered to
be 4%.
Blood pressure and heart rate. The effec ts of anti-
hypertensive therap y on heart rate and blood pressure are
show n in Table I. All patients achieved the goal of therapy.
There were no differences between responders and nonre-
spondcrs (in regard to either left ventricular mass or filling)
with respect to reduction of blood pressure after therapy
(19 =: 8 versus 20 =: 7 mm Hg systolic, and 17 =: 4 versus
19 ..!.. 6 mm Hg diastolic , respectively, both p = NS (Fig.
2). Even though the subjects had not taken antihypertensive
drugs for 24 to 48 hours at the time of the treatment radio-
nuclide filling studies, systolic blood pressures remained
slightly lower than the baseline values (148 ± 16 versus
158 ± 13 mm Hg, p < 0.05) but were similar in patients
whose filling rate increased and in those in whom it did not.
A slight increase in heart rate at rest was noted during
ant ihypertensive therapy when all pat ients were considered
Results
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Figure 3. Changes in left ventricular mass and average rapid left
ventricular filling rate during antihypertensive therapy. Open cir-
cles represent the responders, closed circles and closed square
represent the nonresponders (see text). The middle box defines
the limits of intraobservervariability for theechocardiographic and
radionuclide studies.
sponders with respect to changes in geometry of the ven-
tricle . Because the variability of mass attributable to the
observer was 10% in control echocardiograms, " mass re-
sponders" were defined as those patients whose ventricular
mass declin ed by more than 10% (mean plus 2 standard
deviations). Left ventricular mass for the study group as a
whole did not chan ge significantly after treatment (246 ±
94 versus 222 ± 64 g) (Table I). However , in the six
responders the average left ventricular mass change was
- 26 ± 9%; whereas 9 of the 10 nonresponders had a small
increase in left ventricular mass of 5 ± 4%, one nonre-
sponder had an increase of 41% (Fig. 3).
Left ventricular filling rate and ejection fraction. For
the entire study group, the average rapid left ventricular
filling rate improved from 1.95 ± 0 .34 to 2.11 ± 0.54
end-diastolic counts/s (EDCls) , p < 0.05 (Table I). As the
variability of average rapid left ventricular filling rate de-
terminations noted from control sessions was 4%, " filling
rate responders" were defined as patients whose filling rate
increased by more than 4% of the baseline value after an-
tihypertensive therapy. Filling rate improved in seven pa-
tients (mean 0 .26 ± 0 .20 EDCls, p < 0.02), did not change
in eight (0. 12 ± 0.31 EDCls, p = NS) and decreased in
one patient (0. 14 EDCls) (Fig . 3). With the exception of
one patient , the changes in filling rate were not associated
o 0
Principal findings. This study indica tes that pat ients
whose left ventricular mass decreases durin g ant ihyperten -
sive therapy also experience improved left ventricular fill-
ing. Conversely, those patients who do not manifest a re-
duction in left ventricular mass show no improvement in
diastolic function.
Significance of the findings. Changes in left ventricular
mass dur ing antihypertensive therapy have been frequently
studied in recent years ( 10- 12), but related changes in left
ventricular function are less well described . Because im-
paired diastolic performan ce is characte ristic of the ventricle
that becomes hypertrophic in response to a chron ic pressure
overload (6- 8) , the finding of improved diastolic functi on
that parallels regression of left ventricular mass is important ,
imply ing reversal of pathophysiologic processes in the hy-
pertensive left ventricle.
In this and previous studies (13, 14) responses of left
ventricular mass to antih ypertensive therapy were hetero-
geneous. In light of these varied responses, it is always
possible that the measured changes in ventricular mass were
due to variability of measurements rather than to real changes
in left ventricular mass itself. However . the finding of par-
allel improvement in diastolic ventricular function by an
entirely independent method sugges ts that the chan ges (or
lack thereof) in echocardiograph ically measured mass cor-
responded to the actual state of the ventricular muscle itself.
Thus, measurements of left ventricular filling by radio-
nuclide techniques may provide a way to validate changes
in ventricular mass measured echocardiographically .
Previous studies. Inouye et al. ( 15) were unable to con-
sistently demonstrate improve ment in diastolic function after
4 months of antihypertensive drug trea tment in 10 patients
using diuretic, beta-adrenergic blocking and calcium chan-
nel blocking agents, but 7 of 10 patients in their study had
an improvement in the first third filling fraction during dil-
tiazem treatment. They emph asized the failure of a con-
Discussion
with changes in ejection fraction (Fig . 2) . Whe reas heart
rate at the 6 month treatment visit was slightly higher than
at baseline becau se some patients were withdrawn from
treatment , heart rate measured during gated acqui sition was
not different from baseline (68 ± 7 versus 67 ± 8 beats/min ,
p = NS).
Relation between changes in left ventricular mass and
filling. There was an inverse relation between the changes
in left ventricular mass and those in left ventricular filling
rate (Fig. 3). The one patient whose filling rate increased
40% without a chan ge in mass after treatment also had a
48% increase in heart rate and an absolute 12% increa se in
ejection fraction in the posttreatment study . This outlier may
therefore have experienced excessive sympathetic tone dur-
ing the posttreatment study .
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sistent response, but an alternative interpretation of their
results would be that response to treatment was variable.
Heterogeneity of responses. A number of explanations
could account for the differences in the structural and func-
tional responses of the left ventricle to reduction of blood
pressure observed in our study. Left ventricular mass regres-
sion does not always occur in response to reduction in blood
pressure alone (16), and Kobrin et al. (17) reported a dis-
sociation of changes in left ventricular mass from blood
pressure responses to nitrendipine in rats. It is also possible
that the casual (office) blood pressures reported in this study
do not adequately represent the average daily blood pressure
"experienced" by the left ventricle (18,19). Devereux et
al. (20) showed that the correlation between blood pressure
and left ventricular mass is improved when 24 hour am-
bulatory blood pressures are recorded. A comparison of
response rates based on drug regimen in our study would
not be meaningful because the number of patients in each
treatment group was small. Further, the duration of therapy
was only 6 months, which may be too short a study interval
to demonstrate regression of mass in some individuals (21).
Finally, failure of a particular patient to demonstrate regres-
sion of left ventricular mass after a reduction in blood pres-
sure could be due to the presence of a pathologic state
wherein normalization of structure is no longer possible.
Possible mechanisms for improved diastolic function.
In the chronically pressure-overloaded ventricle a mismatch
between energy supply and demand could result in impaired
relaxation through a decline in high energy phosphate levels.
Reduced afterload could, by restoring oxygen sup-
ply/demand balance and augmenting adenosine triphosphate
supply, enhance relaxation (22). Additionally, regression
of left ventricular mass may have restored a more favorable
ratio of effective capillary surface to myofibrillar mass. Fi-
nally, because all of the patients who participated in the
study were taking nitrendipine, it is possible that this cal-
cium channel blocker, by reducing the amount of calcium
released within the cytosol from a relatively energy-deprived
sarcoplasmic reticulum, could have enhanced muscle relax-
ation by a mechanism that was independent of its effect to
reduce afterload. A more precise understanding of the mech-
anisms responsible for improved ventricular relaxation dur-
ing therapy with nitrendipine will require comparative stud-
ies with drugs having equal antihypertensive potency but
with a mechanism of action not involving blockade of cal-
cium entry into the cell.
Clinical significance of the findings. Left ventricular
diastolic function improves in association with the regres-
sion of left ventricular mass (Fig. 3) after antihypertensive
therapy, and this phenomenon may occur independently of
the extent of reduction in blood pressure. Studies of diastolic
ventricular function may provide an important and sensitive
means to identify desirable target organ responses to anti-
hypertensive therapy, as well as to detect subtle changes of
cardiac function in hypertensive individuals. Larger thera-
peutic trials will be required to delineate the ultimate use-
fulness of this technique and to identify the variables pre-
dicting favorable responses of diastolic function to
antihypertensive therapy.
We are grateful to Ellen J. McCabe, RN, Jyl T. Munson and Gilda A.
McCurdy. NMRT for technical assistance. to Arnold M. Katz, MD for
review of the manuscript and to Richard P. Spencer, MD, PhD for nuclear
medicine support.
References
I. Saragoca MA, Tarazi RC. Left ventricular hypertrophy in rats with
renovascular hypertension. Hypertension 1981;3(suppl 2): 171-6.
2. Strauer B. Ventricular function and coronary hemodynamics in hy-
pertensive heart disease. Am J Cardiol 1979;44:999-1006.
3. Borer JS, Jason M, Devereux RB, et al. Function of the hypertrophied
ventricle at rest and during exercise: hypertension and aortic stenosis.
Am J Med 1983;75(suppl):34-9.
4. Paulus WJ, Brutsaert DL. Relaxation abnormalities in cardiac hyper-
trophy. Eur Heart J 1982;3(suppl A): 133-7.
5. Hirota Y. A clinical study of left ventricular relaxation. Circulation
1980;62:756-63.
6. Fouad FM. Tarazi RC, Gallagher JH, Macintyre WJ, Cook SA. Ab-
normal left ventricular relaxation in hypertensive subjects. Clin Sci
1980 (suppl 6):4115-45.
7. Inouye I. Massie BM, Loje D, et al. Abnormal left ventricular filling:
an early finding in mild-to-moderate systemic hypertension. Am J
Cardiol 1984;53:120-6.
8. Smith V-E, Schulman P. Karimeddini M, White WB. Meeran MK,
Katz AM. Rapid left ventricular filling in left ventricular hypertrophy
II. Pathologic hypertrophy. J Am Coil Cardiol 1985;5:869-74.
9. Devereux RB, Reichek N. Echocardiographic determination of left
ventricular mass in man. Circulation 1977;55:613-8.
10. Drayer JIM, Gardin JM, Weber MA. Aronow WS. Cardiac muscle
mass during vasodilation therapy of hypertension. Clin Pharmacol
Ther 1983;6:727-32.
II. Reichek N, Franklin BB, Chandler T, Muhammad A, Plappert T, S1.
John Sutton M. Reversal uf left ventricular hypertrophy by anti-
hypertensive therapy. Eur Heart J 1982;3(suppl A):165-9.
12. Dunn FG. Oigman W, Ventura HO, Messerli FH, Kobrin I, Frolich
ED. Enalapril improves systemic and renal hemodynamics and allows
regression of left ventricular mass in essential hypertension. Am J
Cardiol 1984;53:105-8.
13. Fouad FM. Nakashima Y, Tarazi RC. Salcedo EE. Reversal of left
ventricular hypertrophy in hypertensive patients treated with meth-
yldopa. Lack of association with blood pressure control. Am J Cardiol
1982;49:795-80I.
14. Drayer JIM, Gardin JM, Weber MA, Aronow WS. Changes in ven-
tricular septal thickness during diuretic therapy. Clin Pharmacol Ther
1982;32:283-8.
15. Inouye IK, Massie BM, Loge X, Simpson P, Tubau JF. Failure of
antihypertensive therapy with diuretic, beta blocking and calcium
channel-blocking drugs to consistently reverse left ventricular diastolic
filling abnormalities. Am J Cardiol 1984;53:1583-7.
16. Sen S. Tarazi RC. Regression of myocardial hypertrophy and influence
of adrenergic nervous system. Am J Physiol 1983;13:H97-101.
17. Kobrin I, Sesoka S, Pegram BL, Frohlich ED. Reduced cardiac mass
by nitrendipine is dissociated from systemic or regional hemodynamic
changes in rats. Cardiovasc Res 1984;18:158-62.
18. Floras JS, Hassan MO, Sever PS, Jones JV, Osikoska B, Sleight P.
1454 SMITH ET AL.
DIASTOLIC FUNCTION, ANTIHYPERTENSIVE THERAPY
lACC Vol. 8, No.6
December 1986:1449-54
Cuff and ambulatory blood pressure in subjects with essential hyper-
tension, Lancet 1981;2:107-9,
19. White WB, Smith V-E, McCabe EJ, Meeran MK. Effects of chronic
nitrendipine on casual (office) and 24-hour ambulatory blood pressure.
Clin Pharmacol Ther 1985;38:60-4.
20. Devereux RB, Pickering TG, Harshfield GA, et at. Left ventricular
hypertrophy in patients with hypertension: importance of blood pres-
sure response to regularly occurring stress. Circulation 1983;68:470-6.
21. Wollam GL, Hall WD, Porter V, et at. Time course of regression of
left ventricular hypertrophy in treated hypertensive patients. Am J
Med 1983;75(suppl):I00-9.
22. Shigakawa M, Dougherty JP, Katz AM. Reaction mechanism of Cal +
dependent ATP hydrolysis by skeletal muscle sarcoplasmic reticulum
in the absence of added alkali salts. I. Characterization of steady state
ATP hydrolysis and comparison of that in the presence of K. J BioI
Chern 1978;253:1442-50.
